Omadacycline as a promising tetracycline alternative for treating community-acquired bacterial pneumonia: Indian experience

IF 1.4 4区医学 Q4 IMMUNOLOGY

Indian Journal of Medical Microbiology Pub Date : 2025-03-30 DOI:10.1016/j.ijmmb.2025.100833

Yamuna Devi Bakthavatchalam , Yuvasri Manokaran , Ranjan Adhiya , Kamini Walia , Balaji Veeraraghavan

{"title":"Omadacycline as a promising tetracycline alternative for treating community-acquired bacterial pneumonia: Indian experience","authors":"Yamuna Devi Bakthavatchalam , Yuvasri Manokaran , Ranjan Adhiya , Kamini Walia , Balaji Veeraraghavan","doi":"10.1016/j.ijmmb.2025.100833","DOIUrl":null,"url":null,"abstract":"<div><div>Omadacycline, a novel tetracycline that has been approved for the treatment of community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSIs). In the present study, we evaluated the in-vitro activity of omadacycline against bacterial pathogens causing CABP. Non-duplicate isolates of methicillin susceptible Staphylococcus aureus (MSSA) (n = 105), methicillin resistant S. aureus (MRSA) (n = 102), Streptococcus pneumoniae (n = 100) and Moraxella catarrhalis (n = 102) were included. The minimum inhibitory concentration of omadacycline and other comparators were determined using the broth microdilution method. Overall, omadacycline potently inhibited MSSA (MIC90 0.25 mg/L), MRSA (MIC90 0.5 mg/L), S. pneumoniae (MIC90 0.06 mg/L) and M. catarrhalis (MIC90 0.12 mg/L) isolates. This finding reiterates that omadacycline could be a potential treatment alternative for treating severe CABP.</div></div>","PeriodicalId":13284,"journal":{"name":"Indian Journal of Medical Microbiology","volume":"55 ","pages":"Article 100833"},"PeriodicalIF":1.4000,"publicationDate":"2025-03-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Indian Journal of Medical Microbiology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0255085725000465","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Omadacycline, a novel tetracycline that has been approved for the treatment of community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSIs). In the present study, we evaluated the in-vitro activity of omadacycline against bacterial pathogens causing CABP. Non-duplicate isolates of methicillin susceptible Staphylococcus aureus (MSSA) (n = 105), methicillin resistant S. aureus (MRSA) (n = 102), Streptococcus pneumoniae (n = 100) and Moraxella catarrhalis (n = 102) were included. The minimum inhibitory concentration of omadacycline and other comparators were determined using the broth microdilution method. Overall, omadacycline potently inhibited MSSA (MIC₉₀ 0.25 mg/L), MRSA (MIC₉₀ 0.5 mg/L), S. pneumoniae (MIC₉₀ 0.06 mg/L) and M. catarrhalis (MIC₉₀ 0.12 mg/L) isolates. This finding reiterates that omadacycline could be a potential treatment alternative for treating severe CABP.

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

Indian Journal of Medical Microbiology IMMUNOLOGY-

CiteScore

2.20

自引率

0.00%

发文量

154

审稿时长

73 days

期刊介绍： Manuscripts of high standard in the form of original research, multicentric studies, meta analysis, are accepted. Current reports can be submitted as brief communications. Case reports must include review of current literature, clinical details, outcome and follow up. Letters to the editor must be a comment on or pertain to a manuscript already published in the IJMM or in relation to preliminary communication of a larger study. Review articles, Special Articles or Guest Editorials are accepted on invitation.